BCL2 and leukemia: The possibility of delivering siRNAs via modified silver nanoparticles into malignant neoplasm cell lines (two types of leukemia and adenocarcinoma of the cervix) and the targeted effect of siRNAs of the group aimed at silencing the bcl2 family were studied.